Osteoarthritis Injectables

Global Osteoarthritis Injectables Market to Reach US$10.0 Billion by 2030

The global market for Osteoarthritis Injectables estimated at US$7.5 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Hyaluronic Acid Injections, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Corticosteroid Injections segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 7.8% CAGR

The Osteoarthritis Injectables market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Osteoarthritis Injectables Market – Key Trends & Drivers Summarized

How Are Osteoarthritis Injectables Transforming Pain Management and Joint Care?

The osteoarthritis injectables market has gained significant traction as non-surgical treatment options for managing joint pain and inflammation become increasingly preferred. With osteoarthritis (OA) affecting millions worldwide, patients and healthcare providers are seeking minimally invasive solutions to delay or avoid joint replacement surgery. Injectable therapies, including corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell-based treatments, are being widely adopted due to their ability to provide targeted pain relief, improve joint mobility, and enhance cartilage health. The aging global population and rising obesity rates—two major risk factors for OA—are further fueling the demand for effective injectables that offer prolonged relief without the side effects associated with oral pain medications.

What Role Do Emerging Biologic and Regenerative Therapies Play in Osteoarthritis Treatment?

The landscape of osteoarthritis treatment is shifting with the increasing adoption of biologic injectables and regenerative medicine approaches. PRP therapy, which utilizes the patient`s own blood-derived growth factors, has gained popularity as a promising alternative to traditional steroid injections. Stem cell-based therapies are also emerging, offering the potential for cartilage regeneration and long-term disease modification rather than just symptomatic relief. Additionally, advancements in hyaluronic acid formulations, including cross-linked and combination therapies, are improving the durability and efficacy of viscosupplementation. Research into gene therapy and monoclonal antibodies targeting inflammatory pathways is also underway, promising next-generation injectable treatments that could revolutionize OA management.

What Are the Key Challenges Limiting the Adoption of Osteoarthritis Injectables?

Despite their effectiveness, several barriers exist in the widespread adoption of osteoarthritis injectables. High treatment costs, particularly for biologic and stem cell-based therapies, remain a significant concern, limiting accessibility for many patients. Additionally, variability in clinical outcomes and the lack of standardized protocols for emerging regenerative treatments pose challenges for regulatory approval and physician adoption. Some injectable therapies, such as corticosteroids, have been associated with potential side effects, including cartilage degradation with prolonged use, leading to cautious prescribing practices. However, ongoing research and clinical trials are working to address these limitations, refining formulations and optimizing dosing regimens to enhance treatment efficacy and safety.

What’s Fueling the Growth of the Osteoarthritis Injectables Market?

The growth in the osteoarthritis injectables market is driven by several factors, including the increasing prevalence of osteoarthritis, rising demand for minimally invasive treatments, and advancements in biologic and regenerative therapies. The growing preference for outpatient and in-office procedures has boosted the adoption of injectable therapies over surgical interventions. Additionally, the expansion of reimbursement policies covering hyaluronic acid and PRP injections in various countries is supporting market growth. The rising geriatric population, along with increasing investments in R&D for novel osteoarthritis therapeutics, is further accelerating market expansion. The emergence of next-generation

SCOPE OF STUDY:

The report analyzes the Osteoarthritis Injectables market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Injection (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet-Rich Plasma Injections, Placental Tissue Matrix Injections, Acetylsalicylic Acid Injections, Other Injections); Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Other Anatomies); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Anika Therapeutics, Inc.
• Arthrex, Inc.
• Bayer AG
• Bioventus LLC
• Boehringer Ingelheim International GmbH
• Ferring Pharmaceuticals Inc.
• Fidia Farmaceutici S.p.A.
• Flexion Therapeutics, Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sanofi S.A.
• Seikagaku Corporation
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.